Best dividend large-cap healthcare stocks for 2026

Large-cap healthcare stocks with dependable dividends are a reliable choice for investors seeking long-term stability, income, and defensive sector exposure. These companies operate across pharmaceuticals, diagnostics, and insurance, with business models built to weather economic cycles.

Max Healthcare Institute’s scale, case-mix, and operating excellence support steady margins, free cash flow, and prudent capital allocation. EssilorLuxottica dominates global eyewear through vertical integration, combining lens manufacturing with iconic brands like Ray-Ban and Oakley. Gilead Sciences develops innovative antiviral and oncology therapies, maintaining leadership in HIV treatments with flagship drug Biktarvy.

Together, these companies represent some of the best dividend large-cap healthcare stocks to consider for income-focused portfolios. Each one offers a unique edge, making them strong contenders for 2025.

Roboforex R-Trader gives you access to over 10,000 stocks, ETFs, commodities, and crypto. All of the stocks mentioned in this article are available for purchase there.

Before we dive into each company, let`s take a look at how your investment would have performed if you had invested in stocks mentioned in this article.

Now, let`s take a closer look at each of the companies:

  • McKesson (NYSE:MCK)

    McKesson Corporation is a leading healthcare distribution and services company specializing in pharmaceutical supply chain management, medical supplies, and healthcare technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson has grown into one of the largest healthcare companies in the United States, playing a critical. The company serves hospitals, pharmacies, and healthcare providers, helping to streamline operations and improve patient outcomes. supporting balanced exposure and.

    With an extensive global distribution network, McKesson delivers pharmaceuticals and medical products to thousands of locations, supporting both independent healthcare providers and large-scale institutions. The company is also a key player in healthcare technology, offering advanced data analytics, automation, and supply chain solutions that enhance efficiency and reduce costs. By continuously innovating and expanding its reach, McKesson remains a vital force in the healthcare industry, ensuring access to essential medicines and improving overall healthcare.

    McKesson financial statements

    Analysts recommendation: 1.65

    Financial Health

    • Return on assets (ROA): 4.33%
    • Return on equity (ROE): N/A
    • Return on investment (ROI): 66.9%

    Profitability

    • Gross margin: 3.45%
    • Operating margin: 1.54%
    • Net profit margin: 1.09%

    Growth

    • EPS (past 5 years): 39.07%
    • EPS (current): 34.64
    • EPS estimate (next quarter): 9.16
    • EPS growth (this year): 38%
    • EPS growth (next year): 12.63%
    • EPS growth (next 5 years): 14.67%
    • EPS growth (quarter-over-quarter): 378.72%
    • Sales growth (past 5 years): 9.22%
    • Sales growth (quarter-over-quarter): 11.4%

    💡 Why invest in McKesson?

    McKesson`s robust profile makes it a tempting pick for investors seeking exposure to the ever-evolving healthcare sector globally:

    • Healthcare Distribution Leader: McKesson boasts a leading position in pharmaceutical distribution across North America, delivering a third of all drugs used in the region with predictable revenue streams and growth potential while maintaining disci.
    • Diversified Service Offerings: Recognizing the changing healthcare landscape, McKesson expands beyond traditional drug distribution into medical-surgical supplies, laboratory equipment, and healthcare IT solutions for strategic growth.
    • Digital Technology Integration: McKesson's technology-driven platforms enhance patient care and operational efficiency throughout the ecosystem while maintaining disciplined execution and strong partnerships across the healthcare value chain.
    • Broad Geographic Reach: With operations spanning North America and Europe, McKesson caters to a diverse customer base and benefits from significant growth opportunities across various regional healthcare markets while maintaining disciplined execut.

    🐌 Key considerations before investing in McKesson

    McKesson navigates reimbursement changes, regulatory scrutiny, and margin pressure, requiring disciplined execution, cost control:

    • Healthcare Regulatory Complexity: Evolving regulations surrounding drug pricing, healthcare reform, and data privacy can impact McKesson`s operations and necessitate costly compliance measures requiring continuous adaptation strategies.
    • Ongoing Legal Challenges: McKesson has faced legal challenges regarding its role in the opioid epidemic, generating negative publicity and potential reputation impact requiring careful monitoring and strategic responses while maintaining discipline.
    • Regional Competitor Pressure: Smaller regional players and online pharmacies are vying for market share, challenging McKesson`s dominant position through innovation and competitive pricing strategies requiring vigilance while maintaining discipline.
    • Industry Dependency Risk: Heavy reliance on pharmaceutical distribution as a primary revenue source creates exposure to industry-specific risks including drug pricing pressures, regulatory changes, and evolving market dynamics affecting the.

    Final thoughts on McKesson

    McKesson Corporation`s leadership in pharmaceutical distribution, diverse service offerings, and technology integration create compelling opportunities for long-term investors seeking exposure to the essential healthcare supply. However, the evolving regulatory landscape, legal challenges, rising competition, and reliance on other industry players warrant careful consideration of both opportunities and risks. Like a vital artery in the healthcare system, McKesson`s distribution network remains essential to delivering medicines and medical products, positioning it strategically despite ongoing industry.

  • Cardinal Health (NYSE:CAH)

    Cardinal Health is a multinational healthcare services and products company that provides pharmaceuticals, medical supplies, and solutions to healthcare providers worldwide. The company was founded in 1971 in Dublin, Ohio, originally as Cardinal Foods before shifting its focus to pharmaceutical distribution. Over the years, it has grown into a critical player in the healthcare supply chain, ensuring the efficient delivery of essential medical products.

    Cardinal Health operates through two main business segments encompassing pharmaceutical distribution and medical products for healthcare providers across nationwide and international markets. Its pharmaceutical division supplies medications to hospitals, pharmacies, and healthcare facilities, while its medical segment provides surgical supplies, laboratory products, and patient care solutions. With a strong focus on logistics, Cardinal Health helps healthcare providers optimize supply chain efficiency, reduce costs, and improve patient care outcomes.

    Cardinal Health financial statements

    Analysts recommendation: 1.65

    Financial Health

    • Return on assets (ROA): 3.5%
    • Return on equity (ROE): N/A
    • Return on investment (ROI): 26.14%

    Profitability

    • Gross margin: 3.69%
    • Operating margin: 1.23%
    • Net profit margin: 0.68%

    Growth

    • EPS (past 5 years): N/A
    • EPS (current): 6.95
    • EPS estimate (next quarter): 2.32
    • EPS growth (this year): 19.4%
    • EPS growth (next year): 12.43%
    • EPS growth (next 5 years): 15.18%
    • EPS growth (quarter-over-quarter): 10.88%
    • Sales growth (past 5 years): 7.8%
    • Sales growth (quarter-over-quarter): 18.8%

    💡 Why invest in Cardinal Health?

    Cardinal Health offers several potential advantages for investors seeking exposure to the healthcare distribution industry:

    • Critical Supply Chain: As a leading distributor of pharmaceuticals and medical products, Cardinal Health plays an essential role in the healthcare supply chain, ensuring reliable delivery of critical medicines to providers nationwide.
    • Revenue Stream Diversification: The company`s pharmaceutical distribution and medical products segments provide diversified revenue streams, reducing reliance on any single market while capturing growth opportunities across healthcare channels.
    • Distribution Network Scale: Cardinal Health`s extensive size and scale enable it to leverage its nationwide distribution network effectively, negotiate favorable supplier terms, and achieve significant operational efficiencies across operations.
    • Demographic Growth Tailwinds: The healthcare industry continues expanding driven by aging population demographics and rising demand for medical services, creating sustained growth opportunities for Cardinal Health`s distribution services.

    🐌 Key considerations before investing in Cardinal Health

    However, before investing in Cardinal Health, investors should carefully consider these significant potential challenges:

    • Healthcare Policy Uncertainty: The healthcare industry faces heavy regulation with frequent government policy changes impacting reimbursement rates and operational requirements, creating ongoing compliance costs and strategic uncertainty.
    • Intense Distribution Competition: The pharmaceutical distribution markets face intense competition from established players like McKesson and Cencora plus new entrants, pressuring margins and requiring continuous technology investment.
    • Supply Chain Vulnerability: Cardinal Health faces operational risks from product availability issues, transportation disruptions, and inventory management challenges that can significantly impact business operations and overall profitability.
    • Economic Recession Exposure: Economic downturns and healthcare spending reductions can negatively affect demand for medical products, delay hospital capital expenditures, and pressure reimbursement rates for Cardinal Health operations.

    Final thoughts on Cardinal Health

    Cardinal Health`s role as a healthcare distribution leader with diversified revenue streams and operational scale offers potential advantages for investors seeking exposure. However, the complex regulatory environment, intense competition, supply chain risks, and economic factors necessitate thorough consideration before investing in the company. Thorough research on Cardinal Health`s market share, financial performance, and the overall healthcare industry trends remains crucial before making investment decisions.

  • United Therapeutics (NYSE:UTHR)

    United Therapeutics is a biotechnology company specializing in the development and commercialization of innovative therapies for pulmonary hypertension and other life-threatening diseases. Founded in 1996 and headquartered in Silver Spring, Maryland, the company was established with a mission to address unmet medical needs through cutting-edge science. United Therapeutics has grown into a leading player in the biotech sector, leveraging advanced technologies to improve patient outcomes worldwide.

    The company is best known for its successful treatments for pulmonary arterial hypertension, including the widely prescribed Remodulin, Tyvaso, and Orenitram therapies. Beyond pulmonary hypertension, United Therapeutics actively develops innovative organ transplantation solutions, including 3D-printed organs and advanced xenotransplantation technologies for patients. By combining deep innovation with commitment to addressing rare and serious conditions, the company pushes the boundaries of biotechnology to extend lives.

    United Therapeutics financial statements

    Analysts recommendation: 1.62

    Financial Health

    • Return on assets (ROA): 13.14%
    • Return on equity (ROE): 20.04%
    • Return on investment (ROI): 19.3%

    Profitability

    • Gross margin: 88.59%
    • Operating margin: 48.69%
    • Net profit margin: 40.65%

    Growth

    • EPS (past 5 years): N/A
    • EPS (current): 26.39
    • EPS estimate (next quarter): 7.07
    • EPS growth (this year): 12.1%
    • EPS growth (next year): 10.69%
    • EPS growth (next 5 years): 9.23%
    • EPS growth (quarter-over-quarter): 12.12%
    • Sales growth (past 5 years): 14.71%
    • Sales growth (quarter-over-quarter): 6.8%

    💡 Why invest in United Therapeutics?

    United Therapeutics demonstrates key advantages that make it an attractive investment in the specialized biotechnology sector:

    • Rare Disease Specialization: The company primarily targets rare and life-threatening diseases with limited treatment options, creating high unmet medical needs and premium pricing opportunities that generate exceptionally strong profit margins.
    • First-Mover Treatment Advantage: United Therapeutics has successfully developed and commercialized several first-in-class therapies for pulmonary arterial hypertension, providing significant competitive advantages through market leadership.
    • Regenerative Medicine Pipeline: While pulmonary arterial hypertension remains the core focus, the company actively expands into organ transplantation and regenerative medicine including 3D-printed organs and xenotransplantation technologies.
    • Robust Intellectual Property: United Therapeutics maintains a comprehensive patent portfolio protecting its innovative products and manufacturing processes, creating substantial barriers to entry for competitors and extending revenue streams.

    🐌 Key considerations before investing in United Therapeutics

    However, investors should carefully consider the challenges facing United Therapeutics in its competitive biotechnology sector:

    • Rare Disease Competition: The biotechnology industry faces intense competition from numerous well-funded companies developing treatments for similar rare diseases, creating meaningful risks of market share erosion and pricing pressure.
    • Complex Regulatory Challenges: Drug development and approval processes involve complex regulatory requirements subject to frequent changes, which can significantly impact product development timelines and commercialization strategies.
    • Clinical Trial Volatility: The biotechnology sector experiences significant stock price volatility with shares fluctuating dramatically based on clinical trial results, regulatory approval decisions, and broader market sentiment shifts.
    • Product Concentration Dependency: While United Therapeutics pursues pipeline diversification, its commercial success remains heavily dependent on the continued strong performance of its core pulmonary arterial hypertension product portfolio.

    Final thoughts on United Therapeutics

    United Therapeutics` deep focus on orphan diseases and innovative pipeline expansion create compelling opportunities for long-term investors seeking specialized biotechnology exposure. However, investors must carefully weigh intense competition, complex regulatory challenges, sector volatility, and significant product concentration risks in this specialized space. United Therapeutics offers transformative growth potential that is balanced against the inherent uncertainties of biotechnology innovation and ongoing drug commercialization efforts.

  • Cencora (NYSE:COR)

    Cencora is a global pharmaceutical services company that specializes in drug distribution, consulting, and supply chain solutions for healthcare providers and manufacturers. Founded in 2001 as AmerisourceBergen through the merger of AmeriSource Health and Bergen Brunswig, the company rebranded to Cencora to reflect its evolving global presence. Headquartered in Conshohocken, Pennsylvania, Cencora has become one of the largest pharmaceutical distributors in the world, playing a crucial role in ensuring access to essential.

    The company provides a wide range of services, including specialty drug distribution, pharmacy management, and consulting solutions for biotech and pharmaceutical firms. With a strong focus on innovation, Cencora leverages data-driven insights and advanced logistics to enhance supply chain efficiency and improve patient outcomes. By working closely with healthcare providers, manufacturers, and pharmacies, Cencora continues to strengthen its position as a critical partner in the global healthcare ecosystem.

    Cencora financial statements

    Analysts recommendation: 1.8

    Financial Health

    • Return on assets (ROA): 3.33%
    • Return on equity (ROE): 133.47%
    • Return on investment (ROI): 14.85%

    Profitability

    • Gross margin: 3.61%
    • Operating margin: 1.18%
    • Net profit margin: 0.5%

    Growth

    • EPS (past 5 years): N/A
    • EPS (current): 8.32
    • EPS estimate (next quarter): 4.04
    • EPS growth (this year): 14.8%
    • EPS growth (next year): 10.75%
    • EPS growth (next 5 years): 10.44%
    • EPS growth (quarter-over-quarter): -10345.61%
    • Sales growth (past 5 years): 11.09%
    • Sales growth (quarter-over-quarter): 5.5%

    💡 Why invest in Cencora?

    Cencora`s robust profile presents a compelling case for investors seeking exposure to the evolving healthcare distribution sector:

    • Pharmaceutical Distribution Powerhouse: Cencora boasts a commanding presence in the US pharmaceutical distribution landscape, serving a vast network of healthcare providers and pharmacies with consistent volume and predictable revenue streams.
    • Value-Added Service Expansion: Recognizing the shifting healthcare landscape, Cencora diversifies its offerings with clinical trial logistics, specialty drug distribution, and data analytics solutions for strategic growth while maintaining discipli.
    • International Logistics Network: Cencora's integrated logistics network spans key international markets with burgeoning healthcare demands while maintaining distribution excellence and regulatory compliance across all operating regions globally.
    • Technology Innovation Leader: The company's data analytics and digital platforms enhance supply chain visibility across the evolving healthcare landscape while maintaining disciplined execution and strong client engagement worldwide.

    🐌 Key considerations before investing in Cencora

    Like navigating complex market conditions, Cencora faces headwinds requiring careful consideration from investors carefully:

    • Stock Valuation Levels: Like many established healthcare companies, COR`s stock currently sits near multi-year highs, which might limit immediate gains requiring a cautious approach with a patient long-term perspective while maintaining disciplined.
    • Pharmaceutical Regulatory Environment: Evolving healthcare regulations and reimbursement challenges can impact Cencora`s profitability and operational efficiency, requiring close monitoring of regulatory changes and their potential impacts.
    • Distribution Market Competition: Intense competition from other large distributors and emerging direct-to-provider models pressures margins and requires continuous investment to maintain its competitive edge while sustaining profitable growth.
    • Macroeconomic Cycle Vulnerability: Healthcare spending can be impacted by economic downturns, potentially hitting Cencora`s business volume and profitability while requiring monitoring of broader economic trends and potential fluctuations.

    Final thoughts on Cencora

    Cencora`s distribution dominance, value-added services, global expansion, and technology innovation create compelling opportunities for long-term investors seeking exposure to the essential pharmaceutical distribution sector. However, near-peak valuation levels, regulatory uncertainties, intense market competition, and economic cycle sensitivity warrant careful consideration of both growth potential and inherent risks. Like a vital circulatory system delivering life-saving medications throughout the healthcare ecosystem, Cencora`s strategic positioning and operational excellence make it a critical infrastructure player despite.

  • Medpace (NYSE:MEDP)

    Medpace Holdings is a full-service clinical contract research organization that designs and executes complex clinical trials for pharmaceutical, biotechnology, and medical device companies worldwide. Founded in 1992 and headquartered in Cincinnati, Ohio, the company is a trusted partner for navigating the regulatory and clinical development landscape globally. Medpace provides end-to-end clinical development solutions, helping clients bring innovative therapies to market efficiently across multiple therapeutic areas worldwide and globally.

    Medpace offers deep expertise in oncology, cardiology, neurology, and rare diseases, ensuring high-quality clinical trial management for pharmaceutical and biotech companies worldwide. The full-service model includes in-house laboratory services, regulatory consulting, and data management for seamless coordination and improved study outcomes worldwide. By leveraging deep scientific expertise and advanced technology platforms, Medpace drives innovation in clinical research and supports life-saving treatment development worldwide.

    Medpace financial statements

    Analysts recommendation: 3.47

    Financial Health

    • Return on assets (ROA): 16.4%
    • Return on equity (ROE): 70.23%
    • Return on investment (ROI): 104.92%

    Profitability

    • Gross margin: 71.06%
    • Operating margin: 21.63%
    • Net profit margin: 17.83%

    Growth

    • EPS (past 5 years): 36.5%
    • EPS (current): 15.3
    • EPS estimate (next quarter): 4.19
    • EPS growth (this year): 26.9%
    • EPS growth (next year): 12.41%
    • EPS growth (next 5 years): 13.91%
    • EPS growth (quarter-over-quarter): 28.34%
    • Sales growth (past 5 years): 19.62%
    • Sales growth (quarter-over-quarter): 32%

    💡 Why invest in Medpace?

    Medpace provides fundamental strengths for investors seeking exposure to clinical research and growth potential in drug development:

    • Clinical Research Leadership: Medpace operates as a leading full-service contract research organization, providing comprehensive clinical trial management that enables pharmaceutical and biotech companies to navigate complex drug development.
    • Comprehensive Integrated Services: The company`s full-service model includes in-house laboratory services, regulatory consulting, and data management capabilities, creating operational efficiencies and competitive advantages in the CRO market.
    • Specialized Therapeutic Expertise: Medpace specializes in complex therapeutic areas including oncology, cardiology, neurology, and rare diseases, providing deep clinical expertise that attracts high-value clients and strategic partnerships globally.
    • Strong Financial Performance: The company demonstrates exceptional financial metrics with high ROE, strong profit margins, and consistent revenue growth, reflecting effective operational execution and market positioning in the CRO industry.

    🐌 Key considerations before investing in Medpace

    However, Medpace faces key challenges and risks that could meaningfully impact performance in the competitive CRO sector:

    • Client Spending Dependency: Medpace`s performance depends heavily on pharmaceutical and biotechnology industry R&D spending, making it vulnerable to budget cuts, regulatory changes, and economic downturns affecting client spending on clinical trials.
    • Competitive CRO Landscape: The CRO industry faces intense competition from large established players and specialized service providers, pressuring margins and requiring continuous investment in advanced capabilities and technology worldwide.
    • Complex Trial Execution: Clinical trials involve inherent risks including patient recruitment challenges, regulatory delays, and study protocol modifications that can meaningfully impact project timelines, costs, and overall profitability.
    • Strict Regulatory Requirements: The company operates in heavily regulated environments requiring strict compliance with FDA, EMA, and international regulatory standards, creating significant operational complexity and potential compliance costs.

    Final thoughts on Medpace

    Medpace`s strong leadership in clinical research services and its integrated full-service model create compelling opportunities in the essential drug development market. However, investors must carefully consider industry dependency, competitive pressures, and inherent clinical trial execution risks that characterize the CRO sector. Medpace`s specialized therapeutic expertise and strong financial performance position it well for continued growth in global pharmaceutical services operations and markets.

  • Teva Pharmaceutical Industries (NYSE:TEVA)

    Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company headquartered in Tel Aviv, specializing primarily in generic drugs, branded medications, and active pharmaceutical ingredients. Founded in 1901 as a wholesale drug business in Jerusalem, Teva has grown into the world largest generic drug manufacturer and the twenty-sixth largest pharmaceutical company globally. The company serves patients in approximately fifty-seven markets with over thirty-six thousand employees worldwide.

    Teva branded portfolio includes Austedo for Huntington disease and tardive dyskinesia, Ajovy for migraine prevention, and the legacy Copaxone for multiple sclerosis. The company operates manufacturing facilities across Israel, North America, Europe, Australia, and South America, producing hundreds of generic medications that serve as affordable alternatives to branded pharmaceuticals for millions of patients around the world.

    Teva Pharmaceutical Industries financial statements

    Analysts recommendation: N/A

    Financial Health

    • Return on assets (ROA): N/A
    • Return on equity (ROE): N/A
    • Return on investment (ROI): N/A

    Profitability

    • Gross margin: N/A
    • Operating margin: N/A
    • Net profit margin: N/A

    Growth

    • EPS (past 5 years): N/A
    • EPS (current): N/A
    • EPS estimate (next quarter): N/A
    • EPS growth (this year): N/A
    • EPS growth (next year): N/A
    • EPS growth (next 5 years): N/A
    • EPS growth (quarter-over-quarter): N/A
    • Sales growth (past 5 years): N/A
    • Sales growth (quarter-over-quarter): N/A

    💡 Why invest in Teva Pharmaceutical Industries?

    Teva holds the leading global position in generic pharmaceuticals with diversified revenue across branded and generic segments:

    • Global Generic Dominance: As the world largest generic drug manufacturer by volume, Teva benefits from unmatched scale in production, distribution, and regulatory expertise across dozens of international markets and therapeutic categories.
    • Branded Drug Pipeline: Key specialty medications including Austedo for neurological disorders and Ajovy for migraine prevention provide higher-margin revenue streams that complement the high-volume generic business model.
    • Manufacturing Footprint Scale: Extensive production facilities spanning five continents enable cost-efficient local manufacturing, rapid market entry for new generics, and resilience against supply chain disruptions in individual regions.
    • Healthcare Cost Pressure Tailwinds: Growing global pressure to reduce healthcare expenditures drives increasing demand for affordable generic alternatives, positioning Teva to benefit from government and insurer cost-containment initiatives.

    🐌 Key considerations before investing in Teva Pharmaceutical Industries

    Legal liabilities, intense pricing competition, and execution challenges create meaningful risks for Teva investors:

    • Legal And Regulatory Exposure: Teva has faced significant legal settlements including price-fixing fines, opioid litigation payments, and antitrust penalties that have materially impacted financial performance and created ongoing legal uncertainty.
    • Generic Pricing Erosion: Intense competition among generic manufacturers combined with purchasing consolidation by pharmacy benefit managers creates persistent downward pressure on generic drug prices and profit margins.
    • Debt Burden Concerns: Historical acquisition-driven growth strategies, particularly the Actavis Generics purchase, left Teva with substantial debt levels that constrain financial flexibility and require ongoing deleveraging efforts.
    • Branded Drug Patent Cliff: Revenue from legacy branded products faces ongoing competitive threats from biosimilars and newer therapies, requiring continuous pipeline investment to offset declining sales from maturing product lines.

    Final thoughts on Teva Pharmaceutical Industries

    Teva Pharmaceutical Industries stands as the undisputed global leader in generic pharmaceuticals with a vast manufacturing network and a growing portfolio of branded specialty drugs. The company benefits from structural demand for affordable medications worldwide and scale advantages in generic production. Investors should carefully weigh the significant legal exposure, debt obligations, and competitive pricing dynamics against the long-term defensive characteristics of the generic drug market.

  • Gilead Sciences (NYSE:GILD)

    Gilead Sciences Inc. is a leading biopharmaceutical company specializing in antiviral and oncology therapies for patients worldwide, headquartered in Foster City, California. Founded in 1987, Gilead has become a global leader in developing innovative treatments for life-threatening diseases across therapeutic areas globally and in multiple markets. The company maintains strong market positions across HIV, hepatitis, and oncology therapeutic areas while focusing on research and development to advance therapeutic solutions globally.

    Gilead`s core business encompasses a diverse portfolio of therapies targeting HIV, hepatitis B and C, and various cancers for patients. Gilead`s flagship HIV treatment Biktarvy leads the market while oncology products like Yescarta and Trodelvy are gaining traction, providing diversified revenue streams across therapeutic areas. The company is advancing its pipeline with promising candidates such as lenacapavir for HIV prevention and seladelpar for liver diseases worldwide.

    Gilead Sciences financial statements

    Analysts recommendation: 1.69

    Financial Health

    • Return on assets (ROA): 12.52%
    • Return on equity (ROE): 40.66%
    • Return on investment (ROI): 18.57%

    Profitability

    • Gross margin: 78.84%
    • Operating margin: 37.4%
    • Net profit margin: 28.9%

    Growth

    • EPS (past 5 years): -38.13%
    • EPS (current): 6.79
    • EPS estimate (next quarter): 1.86
    • EPS growth (this year): 23.5%
    • EPS growth (next year): 7.12%
    • EPS growth (next 5 years): 26.27%
    • EPS growth (quarter-over-quarter): 142.22%
    • Sales growth (past 5 years): 5.17%
    • Sales growth (quarter-over-quarter): 4.7%

    💡 Why invest in Gilead Sciences?

    Gilead Sciences presents fundamental strengths that position it well for investors seeking stable returns and growth prospects:

    • Proven Treatment Portfolio: Gilead`s established treatments in HIV and hepatitis provide a stable revenue base with flagship drug Biktarvy continuing to lead in sales, generating consistent cash flows for ongoing R&D investments and future growth.
    • Next-Generation Pipeline Innovation: The company is investing in next-generation therapies including long-acting HIV prevention drug lenacapavir and novel oncology treatments like Trodelvy, expanding addressable markets and growth opportunities.
    • Targeted Acquisition Strategy: Recent acquisitions like CymaBay Therapeutics aim to bolster Gilead`s presence in liver diseases and other therapeutic areas, diversifying the portfolio and reducing reliance on existing HIV franchise revenues.
    • Strong Financial Fundamentals: Gilead maintains robust gross margins of 78.7% and operating margins of 45.2%, demonstrating strong pricing power and operational efficiency that support sustained profitability and attractive shareholder returns.

    🐌 Key considerations before investing in Gilead Sciences

    Before investing in Gilead Sciences, consider these important headwinds that could impact future performance and investment returns:

    • Acquisition-Related Earnings Volatility: Significant charges from acquisitions have led to fluctuations in net income with recent earnings declining sharply to $480 million, creating near-term financial performance uncertainty for investors.
    • Healthcare Policy Risks: Potential changes in healthcare policies such as cuts to HIV prevention funding or drug pricing reforms could significantly impact revenues and profitability across Gilead`s core therapeutic franchises and future growth.
    • Competitive Therapeutic Landscape: The biopharmaceutical industry faces intense competition with rivals developing similar therapies that could challenge Gilead`s market share in HIV, hepatitis, and oncology, pressuring pricing and margins.
    • Patent Expiration Exposure: Key products face patent expirations in coming years which could lead to generic competition and revenue erosion, requiring successful pipeline execution to offset declining sales from mature franchises worldwide.

    Final thoughts on Gilead Sciences

    Gilead Sciences maintains a strong position in antiviral and oncology treatments, supported by a robust product portfolio and a pipeline of innovative therapies. While recent financial performance has been affected by acquisition-related charges, the company`s strategic investments and ongoing research efforts position it for potential long-term growth. The company benefits from its established market leadership in HIV treatments and promising oncology pipeline developments that provide a solid foundation for future expansion.

  • HCA Healthcare (NYSE:HCA)

    HCA Healthcare Inc. is a leading healthcare services provider operating hospitals, surgery centers, and urgent care facilities across the United States. The company was founded in 1968 and is headquartered in Nashville, Tennessee, as one of the largest hospital networks worldwide. HCA Healthcare serves millions of patients annually through its extensive and growing network of comprehensive medical facilities and outpatient centers.

    The company manages hospitals, outpatient centers, and specialized services delivering comprehensive medical care including emergency, surgery, maternity, and cancer treatment. HCA Healthcare leverages advanced technology and data-driven approaches to enhance patient outcomes while continuously expanding access to high-quality healthcare services. By maintaining strong operational efficiency and investing in medical technology infrastructure, the company continues to strengthen its overall market leadership position.

    HCA Healthcare financial statements

    Analysts recommendation: 2.07

    Financial Health

    • Return on assets (ROA): 12.44%
    • Return on equity (ROE): N/A
    • Return on investment (ROI): 18.18%

    Profitability

    • Gross margin: 41.5%
    • Operating margin: 16.29%
    • Net profit margin: 8.97%

    Growth

    • EPS (past 5 years): 16.93%
    • EPS (current): 28.34
    • EPS estimate (next quarter): 7.46
    • EPS growth (this year): 44.5%
    • EPS growth (next year): 7.83%
    • EPS growth (next 5 years): 14.7%
    • EPS growth (quarter-over-quarter): 42.37%
    • Sales growth (past 5 years): 6.58%
    • Sales growth (quarter-over-quarter): 6.7%

    💡 Why invest in HCA Healthcare?

    HCA Healthcare offers several compelling advantages for investors seeking exposure to the essential hospital services industry:

    • Nationwide Hospital Network: HCA Healthcare`s extensive network of hospitals and outpatient facilities across multiple states provides significant geographic diversification and economies of scale that create competitive advantages.
    • Non-Cyclical Service Demand: Healthcare represents a fundamentally non-cyclical industry with steady demand regardless of economic conditions, making HCA Healthcare`s essential hospital services relatively resilient during downturns and volatility.
    • Quality Care Excellence: HCA Healthcare prioritizes quality patient care and operational efficiency through advanced technology investments, leading to strong patient satisfaction scores and sustainable competitive positioning in the industry.
    • Demographic Growth Drivers: The aging population and rising demand for healthcare services create sustained long-term growth opportunities for HCA Healthcare`s expanding hospital network and outpatient facilities across its geographic footprint.

    🐌 Key considerations before investing in HCA Healthcare

    However, before investing in HCA Healthcare, investors must carefully evaluate these significant potential challenges and risks:

    • Hospital Regulatory Complexity: The healthcare industry faces heavy regulation with frequent government policy changes impacting reimbursement rates and operational costs, creating significant ongoing compliance burdens for HCA Healthcare.
    • Healthcare Workforce Challenges: The healthcare industry experiences persistent challenges recruiting and retaining qualified nurses and physicians, which significantly impacts operational efficiency and labor costs across HCA Healthcare.
    • Economic Recession Risks: Economic downturns can negatively affect patient volumes and insurance coverage rates, creating significant revenue and margin pressures that impact HCA Healthcare`s financial performance despite providing essential care.
    • Rising Operational Costs: Increasing costs for labor, medical supplies, and technology investments create ongoing margin pressures requiring continuous operational improvements to maintain strong profitability across HCA Healthcare facilities.

    Final thoughts on HCA Healthcare

    HCA Healthcare`s nationwide hospital network, non-cyclical service demand, and quality care excellence create compelling opportunities for investors seeking exposure to the essential healthcare services sector. However, investors must carefully consider the complex regulatory landscape, healthcare workforce challenges, and rising operational costs that characterize the hospital industry. HCA Healthcare`s significant scale and operational expertise position it strategically for continued growth despite ongoing industry challenges and competitive pressures.

  • Ipsen (PA:IPN)

    Ipsen SA is a French biopharmaceutical company headquartered in Boulogne-Billancourt, Paris, focused on drug development and commercialization across three core therapeutic areas: oncology, rare diseases, and neuroscience. Founded in 1929 by Dr. Henri Beaufour as Laboratoires Beaufour, the company has evolved into one of the world top fifteen biopharmaceutical companies in oncology sales. Ipsen medicines are registered in eighty-eight countries with direct commercial presence in over thirty markets.

    The company generated revenue of approximately EUR 3.4 billion in 2024 and employs around five thousand people worldwide. Key products include Cabometyx for advanced kidney and liver cancer, Somatuline for neuroendocrine tumors, Dysport botulinum toxin for neurological and aesthetic indications, and Onivyde for metastatic pancreatic cancer. The Beaufour family maintains a controlling ownership stake through Beech Tree and Highrock entities while shares trade publicly on the Euronext Paris exchange.

    Ipsen financial statements

    Analysts recommendation: N/A

    Financial Health

    • Return on assets (ROA): N/A
    • Return on equity (ROE): N/A
    • Return on investment (ROI): N/A

    Profitability

    • Gross margin: N/A
    • Operating margin: N/A
    • Net profit margin: N/A

    Growth

    • EPS (past 5 years): N/A
    • EPS (current): N/A
    • EPS estimate (next quarter): N/A
    • EPS growth (this year): N/A
    • EPS growth (next year): N/A
    • EPS growth (next 5 years): N/A
    • EPS growth (quarter-over-quarter): N/A
    • Sales growth (past 5 years): N/A
    • Sales growth (quarter-over-quarter): N/A

    💡 Why invest in Ipsen?

    Ipsen operates a focused specialty care platform with leading positions in oncology, rare disease, and neuroscience therapeutics:

    • Oncology Franchise Strength: A robust oncology portfolio anchored by Cabometyx for kidney and liver cancer and Somatuline for neuroendocrine tumors provides durable revenue streams supported by strong clinical evidence and physician loyalty.
    • Rare Disease Growth Platform: Strategic acquisitions including Clementia and Albireo have built a meaningful rare disease presence with first-in-class therapies like Sohonos for fibrodysplasia ossificans progressiva addressing significant unmet medical needs.
    • Dysport Diversified Revenue: The Dysport botulinum toxin franchise generates stable revenue across both therapeutic applications for muscle spasticity and aesthetic medicine, providing cash flow resilience independent of oncology cycles.
    • Consistent Revenue Growth: The company has delivered sustained revenue growth exceeding ten percent annually in recent years, driven by successful product launches and geographic expansion across its focused therapeutic areas.

    🐌 Key considerations before investing in Ipsen

    Concentration in specialty medicine and competitive dynamics in oncology create key risks for Ipsen shareholders:

    • Product Concentration Risk: A significant share of revenue depends on a handful of key products, meaning any clinical setback, patent expiration, or competitive threat to flagship drugs could materially impact overall financial performance.
    • Oncology Competitive Intensity: The oncology market features aggressive competition from large pharmaceutical companies with substantial R&D budgets, requiring continuous innovation and lifecycle management to defend existing market positions.
    • Family Control Governance: The Beaufour family controlling ownership stake creates dual-class governance dynamics that may limit minority shareholder influence on strategic decisions and corporate direction over time.
    • Geographic Revenue Concentration: Despite international operations, a substantial portion of revenue derives from established European markets, exposing the company to regional regulatory changes and healthcare reimbursement policy shifts.

    Final thoughts on Ipsen

    Ipsen has successfully transformed into a focused specialty biopharmaceutical company with leadership positions in oncology and rare diseases complemented by the diversified Dysport franchise. The company benefits from a disciplined acquisition strategy and consistent revenue growth across its therapeutic focus areas. Investors should consider product concentration risks, competitive pressures in oncology, and the implications of family-controlled governance when evaluating the stock.

  • Vertex Pharmaceuticals (NYSE:VRTX)

    Vertex Pharmaceuticals is a biotechnology company specializing in developing and commercializing transformative medicines for serious diseases worldwide. The company was founded in 1989 and is headquartered in Boston, Massachusetts, with a strong focus on medical innovation. Vertex is best known for its groundbreaking treatments for cystic fibrosis, which have significantly improved patient outcomes globally.

    Vertex`s core business focuses on discovering and developing small-molecule drugs targeting genetic disorders and serious medical conditions. Its portfolio includes innovative therapies for cystic fibrosis and ongoing research into treatments for sickle cell disease, beta-thalassemia, and other rare conditions. With a strong emphasis on precision medicine, Vertex leverages cutting-edge science including CRISPR gene-editing technology to develop next-generation therapies.

    Vertex Pharmaceuticals financial statements

    Analysts recommendation: 1.89

    Financial Health

    • Return on assets (ROA): 12.16%
    • Return on equity (ROE): 22.54%
    • Return on investment (ROI): 19.19%

    Profitability

    • Gross margin: 53.66%
    • Operating margin: 39.6%
    • Net profit margin: 32.94%

    Growth

    • EPS (past 5 years): N/A
    • EPS (current): 15.32
    • EPS estimate (next quarter): 5.12
    • EPS growth (this year): 32.9%
    • EPS growth (next year): 10.83%
    • EPS growth (next 5 years): N/A
    • EPS growth (quarter-over-quarter): 4.95%
    • Sales growth (past 5 years): 21.61%
    • Sales growth (quarter-over-quarter): 9.5%

    💡 Why invest in Vertex Pharmaceuticals?

    Vertex Pharmaceuticals presents fundamental strengths for investors seeking stable returns and growth prospects in biotechnology sector:

    • Scientific Innovation Leadership: Vertex stands out for its commitment to cutting-edge research and development, consistently delivering groundbreaking treatments for complex diseases including cystic fibrosis and gene-editing therapies worldwide.
    • Serious Disease Focus: Their expertise lies in tackling life-threatening illnesses like cystic fibrosis and sickle cell disease, offering hope to patients with limited treatment options and commanding premium pricing in global markets.
    • Strong Portfolio Pipeline: Vertex boasts successful drugs like Kalydeco and Trikafta while also actively developing new medications for various serious conditions including CRISPR gene-editing therapies for genetic disorders in the pipeline.
    • Unmet Medical Needs: Vertex prioritizes addressing unmet medical needs driving innovation and development in areas with limited treatment availability, creating significant market opportunities and competitive advantages for growth.

    🐌 Key considerations before investing in Vertex Pharmaceuticals

    Vertex Pharmaceuticals faces several challenges that investors must evaluate carefully before making investment decisions in biotech sector:

    • High Development Costs: Developing new drugs is expensive and time-consuming requiring billions in R&D investments, impacting profitability in the short term and creating financial risks if pipeline candidates fail clinical trials worldwide.
    • Patent Expiration Risks: The expiration of patents on established drugs can lead to a decline in revenue if Vertex fails to successfully replace them with new therapies, creating revenue cliff risks for investors in the market.
    • Regulatory Approval Challenges: Gaining regulatory approval for new medications is a complex and lengthy process impacting the timeline for bringing treatments to market and creating commercialization uncertainties for the company.
    • Limited Product Diversification: Vertex`s heavy reliance on cystic fibrosis treatments creates concentration risk, making the company vulnerable to competitive threats or market changes in this single therapeutic area worldwide.

    Final thoughts on Vertex Pharmaceuticals

    Vertex Pharmaceuticals` commitment to scientific innovation, focus on tackling serious diseases, and promising pipeline create compelling opportunities for long-term investors seeking exposure to the biotechnology sector. However, investors must carefully weigh high development costs, patent expirations, and regulatory hurdles that characterize the biopharmaceutical industry. Vertex leverages cutting-edge science including CRISPR gene-editing technology to develop transformative therapies for patients worldwide.

If you are looking for other dividend opportunities, explore my best dividend large cap basic materials, energy, financial, industrial, retail, semiconductor, tech, utility stocks.